News

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans
Explore Brainstorm Cell Therapeutics' Q1 2025 earnings call highlights, including FDA clearance for their ALS Phase 3b trial, funding efforts, ...